Table 2.
Incidence of “gsp” in “receptive organs”
| Site | Histology (Dysplasia/Neoplasia) | Incidence % (n) | Refs |
|---|---|---|---|
| Thyroid | Toxic thyroid adenoma | 23% (65) | [102–104] |
| Non functional adenoma | 0% (31) | [102, 104] | |
| Carcinoma | 0% (18) | [104, 105] | |
| Pituitary | GH-secreting adenoma | 41% (504) | [106–126] |
| Prolactin-secreting adenoma | 0% (7) | [107] | |
| Non functioning | 3% (32) | [107] | |
| Muscle | Intramuscolar myxoma | 45% (101) | [39, 127, 128] |
| Various myxoid lesions | 0% (105) | [39, 127–130] | |
| Bone | Fibrous dysplasia (FD) | 81% (414) | [127, 131–134] |
| Low grade periosteal osteosarcoma | 0% (11) | [135] | |
| Low grade central osteosarcoma | 3% (35) | [135–137] | |
| Low grade parosteal osteosarcoma | 0% (80) | [135, 137] | |
| Osteofibrous dysplasia | 0% (13) | [132, 134, 138] | |
| Ossifying fibroma | 0% (66) | [131, 132] | |
| Blood | Hematological conditions | 0.6% (512) | [139–141] |
| Kidney | Renal cell carcinoma | 17% (30) | [142] |
| Lung | Mucinous cystoadenoma | 0.5% (208) | [24, 68, 143] |
| Pancreas | Intraduct. Papill. Mucin. Neop.(IPMN) | 58% (809) | [17, 19–21, 30, 68, 144–148] |
| Incipient IPMN | 33% (21) | [149] | |
| Intraduct. Tubulopapill. Neop. (ITPN) | 60% (15) | [146] | |
| Intraepithelial neoplasia (PanIN) | 2% (246) | [20, 150] | |
| Serous cystoadenoma (SCN) | 0% (54) | [20, 144] | |
| Mucin. Cyst.Neop. (MCN) | 0% (31) | [20, 144] | |
| Neuroendocrine tumor | 0% (52) | [20] | |
| Ductal adenocarcinoma (PDAC) | 0.4% (253) | [20, 30, 144, 145, 150] | |
| Biliary tract | IPMN of the bile duct | 23% (120) | [42, 151–153] |
| Biliary intraepithelial neoplasia | 1% (82) | [153, 154] | |
| Stomach | Pyloric gland adenoma | 48% (23) | [41] |
| Gastric adenocarc. of the fundic gland | 24% (29) | [64, 74] | |
| Hyperplastic gastric polyps | 0% (10) | [127] | |
| Foveolar type adenoma | 0% (23) | [41] | |
| Intestinal type adenoma | 0% (34) | [41] | |
| Gastric adenocarcinoma | 0% (71) | [41] | |
| Duodenum | Pyloric gland adenoma | 92% (35) | [41] |
| Gastric foveolar metaplasia | 41% (66) | [66] | |
| Gastric heterotopia | 28% (81) | [66] | |
| Adenocarcinoma | 17% (30) | [66] | |
| Gastroent. neuroen. tum. (GEP-NET) | 0% (31) | [155] | |
| Colon-rectum | Villous adenoma | 67% (55) | [155–158] |
| Tubular villous adenoma | 4% (154) | [155–157] | |
| Tubular adenoma | 0% (28) | [155, 157] | |
| Polyps | 0% (45) | [156] | |
| Adenocarcinoma | 3% (820) | [68, 155–159] | |
| Liver | Normal liver Intrahepat.cholangioc | 12%(43) | [160] |
| Advanc. Intrahepatic cholangiocarc | 3% (38) | [160] | |
| Hepatocell. Adenoma | 4% (179) | [22, 161] | |
| Hepatocell. Carcinoma | 0.8% (245) | [22] | |
| Fluke-ass. cholangiocarcinoma | 9.3% (53) | [23] | |
| Appendix | Low grade app. muc. neop. (LAMN) | 43% (84) | [31, 40, 68, 162, 163] |
| Adenocarcinoma | 46% (106) | [31, 40, 68, 69, 162–164] | |
| Gonads | Leydig cell stromal tumor | 67% (6) | [165] |
| Lobular Endocer. Glandular Hyperpl. | 28% (32) | [166] | |
| Juvenile Ovarian granul. cell tumor | 30% (30) | [167] | |
| Mucinous cystoadenoma | 9% (45) | [68, 168] | |
| Mucinous border line tumor | 4% (53) | [68, 168] | |
| Mucinous cystadenocarcinoma | 2% (45) | [68, 168] | |
| Ovarian granulosa cell tumor | 0% (25) | [169, 170] | |
| Other sex cord stromal tumors | 0% (6) | [170] | |
| Adenocarcinoma | 4% (92) | [166] | |
| Squamous cell carcinoma | 0% (43) | [166] | |
| Adrenocortical | Cortisol producing adenoma | 20% (25) | [28, 90, 171] |
| Adrenocrotical Carcinoma | 3% (40) | [80] |
An extensive list of neoplasias, flanked by gsp prevalence. Numbers in bold correspond to tumors presenting a rate over 10%. In each responsive tissue/organ, incidences in the double digits often pinpoint a single diagnosis that stands out among other virtually gsp negative tumor types. The large majority of other neoplasms are negative, for instance ref [50] analyzed 1126 cases falling within 15 diagnosis and found all negatives